NCT03241940 2025-06-29
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT03186118 2025-06-17
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT06752785 2024-12-31
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Guangzhou Women and Children's Medical Center
Phase 1 Recruiting
NCT03768310 2022-07-21
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Baylor College of Medicine
Phase 1 Withdrawn
NCT05043571 2021-09-14
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
National University Hospital, Singapore
Phase 1 Recruiting
NCT05038696 2021-09-09
ALaCART
National University Hospital, Singapore
Phase 1 Recruiting
NCT02186860 2021-02-10
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown